MinuteCE®
A robust collection of short-form, digestible CE activities that are made to fit into any schedule. With MinuteCE, you’re in control of the content you want, when you want it. To start microlearning, follow these simple steps:
Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
Why choose microlearning?
- Bite-sized episodes
- The most relevant content
- Improved retention
To experience MinuteCE for yourself, select one of the episodes below to start learning!
61-75 of 177
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Ignacio Duran, MD
Wenxin Xu, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Ignacio Duran, MD
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD
Wenxin Xu, MD
- advertisement
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies
Sandy Srinivas, MD
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
MinuteCE®Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP
MinuteCE®Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP
Jeffrey Allen, MD
Nicholas J. Silvestri, MD
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
Implementing CIDP Clinical Guidelines: Optimizing Therapy
MinuteCE®Implementing CIDP Clinical Guidelines: Optimizing Therapy
Nicholas J. Silvestri, MD
Jeffrey Allen, MD
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
- advertisement
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Pasi Antero Jänne, MD, PhD
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
Jeffrey Allen, MD
Nicholas J. Silvestri, MD
